Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Significant Increase in Short Interest

Dogwood Therapeutics, Inc (NASDAQ:DWTX) was the recipient of a significant growth in short interest in April. As of April 30th, there was short interest totaling 125,511 shares, a growth of 169.5% from the April 15th total of 46,578 shares. Based on an average daily volume of 131,384 shares, the short-interest ratio is currently 1.0 days. Currently, 0.4% of the company’s shares are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP bought a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned approximately 0.51% of Dogwood Therapeutics at the end of the most recent quarter. 9.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on DWTX shares. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Dogwood Therapeutics in a research report on Monday, April 27th. Weiss Ratings downgraded shares of Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, April 27th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $12.00.

Dogwood Therapeutics Stock Up 6.5%

Shares of DWTX stock opened at $1.98 on Friday. The firm has a fifty day moving average of $2.12 and a 200-day moving average of $3.65. Dogwood Therapeutics has a 12-month low of $1.28 and a 12-month high of $9.50. The company has a market capitalization of $66.13 million, a price-to-earnings ratio of -0.10 and a beta of 1.68.

Dogwood Therapeutics (NASDAQ:DWTX) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.07. On average, equities analysts expect that Dogwood Therapeutics will post -0.93 EPS for the current year.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical?stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high?throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.